Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Gastroenterol. Jun 28, 2026; 32(24): 119220
Published online Jun 28, 2026. doi: 10.3748/wjg.v32.i24.119220
Published online Jun 28, 2026. doi: 10.3748/wjg.v32.i24.119220
Successful conversion therapy for advanced hepatocellular carcinoma with biliary tumor thrombus and bilateral lobe involvement: A case report
Yu Zhang, Lu-Yang Zhang, Bo Meng, Yun-Jian Wang, Nan-Mu Yang, Min Zhang, Department of Hepatobiliary and Pancreatic Surgery, The Affiliated Cancer Hospital of Zhengzhou University, Henan Provincial Cancer Hospital, Zhengzhou 450008, Henan Province, China
Qiong Li, North Henan Medical University, Xinxiang 453003, Henan Province, China
Author contributions: Zhang Y and Zhang LY contributed to the manuscript writing, editing, and data collection; Wang YJ, Yang NM, and Meng B contributed to the data analysis; Li Q and Zhang M contributed to the conceptualization and supervision of the overall project; all authors have read and approved the final manuscript.
AI contribution statement: We only used AI tools such as Grammarly and DeepL to modify English grammar and polish the language expression of this manuscript. The entire manuscript was independently drafted and revised by the author, and all content was not generated by AI. AI tools are only used for language polishing and assisted translation, and do not involve data analysis or manuscript content writing. The research design and result interpretation were independently completed by the authors without the involvement of any AI tools. There are no numbers or images generated by AI in this manuscript.
Supported by Henan Province Science and Technology Research Project, No. SBGJ202103035.
Informed consent statement: Informed written consent was obtained from the patient for the publication of this report and any accompanying images.
Conflict-of-interest statement: The authors declare that they have no conflicts of interest to disclose.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Corresponding author: Min Zhang, MD, PhD, Department of Hepatobiliary and Pancreatic Surgery, The Affiliated Cancer Hospital of Zhengzhou University, Henan Provincial Cancer Hospital, No. 127 Dongming Road, Zhengzhou 450008, Henan Province, China.
Received: January 22, 2026
Revised: February 12, 2026
Accepted: March 12, 2026
Published online: June 28, 2026
Processing time: 139 Days and 7 Hours
Revised: February 12, 2026
Accepted: March 12, 2026
Published online: June 28, 2026
Processing time: 139 Days and 7 Hours
Core Tip
Core Tip: For advanced bilateral multilobular hepatocellular carcinoma (HCC) with HCC-derived biliary tumor thrombus, conversion therapy using camrelizumab (immunotherapy) combined with apatinib mesylate (targeted therapy) and hepatic radiofrequency ablation successfully reduced tumor burden and eliminated the biliary tumor thrombus, enabling radical surgical resection. This approach resulted in short-term disease-free survival (6 months after surgery) with preserved normal liver function.